Stockholders’ Equity (Deficit) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders’ Equity (Deficit) | Note 7 – Stockholders’ Equity (Deficit)
Common Stock
The Company is authorized to issue shares of common stock and shares of preferred stock. The Company had shares of common stock issued and outstanding as of September 30, 2026. There was preferred stock issued and outstanding as of September 30, 2026.
During the three and nine months ended September 30, 2026, the Company recorded $875,315 of related-party forgiveness of accrued compensation as a capital contribution in additional paid-in capital.
In connection with the PharmAla License Agreement, the Company issued common shares with a value of $889,478 and shares remained issuable under the License Agreement. In the event the Company cannot issue the shares, or at the Company’s election, the Company must settle the obligation in cash totaling $. See Note 6 - PharmAla License Agreement and Share-Settlement Liability for further details.
On May 20, 2026, the Company entered into a Securities Purchase Agreement with investors (the “May Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the May Investors (the “May Offering”), shares of common stock of the Company at a price of $ per share, for aggregate gross proceeds to the Company of approximately $2.0 million. Placement agent fees were $140,000 and proceeds before offering expenses were $1,860,000.
On August 21, 2026, the Company entered into a Securities Purchase Agreement with investors (the “August Investors”) pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to August Investors (the “August Offering”) to sell shares of common stock of the Company at a price of $ per share, for aggregate gross proceeds to the Company of approximately $2.0 million. Placement agent fees were $140,000 and proceeds before offering expenses were $1,860,000.
On October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) and related Registration Rights Agreement with YA II PN, Ltd. (“Yorkville”), providing the Company the right, but not the obligation, to sell up to $20.0 million of common stock from time to time, subject to customary conditions, including an effective resale registration statement. Since inception and through September 30, 2026, we have issued and sold approximately shares of common stock to Yorkville pursuant to the SEPA, including shares of common stock issued in connection with the settlement of Prepaid Advances and shares of common stock upon conversion of the Convertible Notes, for aggregate net proceeds to us of $5,218,006.
Equity Awards and Compensation Arrangements
At the July 22, 2026 Annual Meeting, the Company’s stockholders also approved an amendment to the 2025 Equity Incentive Plan to increase the number of shares available for issuance by shares after giving effect to the Reverse Stock Split.
On June 5, 2026,
On June 2, 2026, the Compensation Committee approved stock option grants to each independent non-employee director to purchase up to shares of common stock under the 2025 Equity Incentive Plan, vesting over three years commencing September 2, 2026 in equal quarterly installments.
On June 2, 2026, the Board approved stock options to executive officers under the 2025 Equity Incentive Plan. The Board also approved a one-time option grant to the Chief Financial Officer to purchase up to shares of common stock. Each grant vests over three years commencing September 2, 2026 in equal quarterly installments.
The options have an exercise price equal to the fair market value of the Company’s common stock on the grant date and vest in equal quarterly installments over 36 months, subject to Dr. Philipson’s continued service as a director.
During the nine months ended September 30, 2026, the Company issued shares of Common Stock, with an aggregate fair value of $46,750, as consideration for services rendered related to media and investor relations activities, strategic communications support, enhancement to the Company’s market visibility and shareholder engagement. The fair value of the shares issued was determined based on the market price of the Company’s Common Stock at the date of issuance and is included in general and administrative expenses in the accompanying condensed statement of operations.
Service Agreement
On June 3, 2024, the Company entered into service agreements with three separate entities, each with a 36-month term. In connection therewith the Company issued an aggregate of restricted shares of Common Stock, ratably to each entity with an aggregate fair value at issuance totaling $4,638,375 which were registered upon the closing of the IPO in December 2024. In addition, each of the entities agreed to and ultimately purchased shares of the Company’s Common Stock at a purchase price of $ per share prior to the effective date of the IPO, resulting in aggregate proceeds of approximately $150,000.
Pursuant to the agreements, the counterparties are obligated to perform certain services, as defined, and the Company is recognizing the fair value of the issued restricted shares as compensation expense over the 36-month term, the requisite service period. During the three months ended September 30, 2026 and 2025, the Company recorded compensation expense of $ in each period, related to the agreement, which is included in general and administrative expenses in the accompanying condensed statements of operations.
Stock Options
On April 2, 2026, the Company granted an aggregate of stock options to two consultants with an exercise price of $ per share and a grant date fair value of $. The stock options have a -year term and % of the stock options vest immediately on the grant date, with options vesting in equal monthly installments over 24 months.
On June 2, 2026, the Company also issued stock options to executive officers, board members, and certain employees with an exercise price of $ per share and a grant date fair value of $. The stock options have a -year term and % of the stock options vest commencing from September 2, 2026, in equal quarterly installments over 36 months. On June 29, 2026, the Company also issued stock options to a new board of director member with an exercise price of $ per share and a grant date fair value of $. The stock options have a -year term and vest in equal quarterly installments over 36 months.
On July 31, 2026, the Company granted Andrew J. Cutler options to purchase approximately shares of common stock at an exercise price of $ per share, in connection with his appointment to the Board of Directors and in lieu of cash board retainer and committee fees. Twenty-five percent of the options vested on the grant date, and the remaining options vest in quarterly installments, subject to Mr. Cutler’s continued service as a director. The options expire on July 31, 2036.
On July 2, 2025, the Company granted an aggregate of stock options issued to certain executives. The stock options have an exercise price of $per share, representing the closing price of the Company’s Common Stock on Nasdaq on the date of grant.
On September 5, 2025, the Company granted an aggregate of stock options to two consultants with an exercise price of $per share and a grant date fair value of $. The stock options have a 10 year term and % of the stock options vest immediately on the grant date, with options vesting in equal monthly installments until September 5, 2027.
The Company also granted stock options to one of the consultants with an exercise price of $ per share and a grant date fair value of $, and a 10 year term that vest solely upon achievement of performance conditions as follows:
For the nine months ended September 30, 2026, the Company recognized stock-based compensation expense of $, consisting of $ related to equity awards and $46,750 related to shares issued for services.
Restricted Stock Units
As of September 30, 2025, 21,680 shares of common stock underlying fully vested restricted stock units had not been legally issued due to administrative delays. These shares had previously been included in shares issued and outstanding and were removed from reported shares outstanding, resulting in a non-cash reclassification of $2 from common stock to additional paid-in capital. The adjustment had no effect on total stockholders’ equity (deficit) or net loss. The shares were subsequently issued during the second quarter of 2026.
On April 30, 2026, the Company granted a consultant restricted stock units under the 2025 Equity Incentive Plan, with each restricted stock unit representing the right to receive one share of the Company’s common stock. Twenty-five percent of the award vested on the grant date, and the remaining restricted stock units vest in four equal quarterly installments through April 30, 2027, subject to continued service. As of September 30, 2026, 1,333 restricted stock units were outstanding, of which were vested and were unvested.
There was $ unrecognized stock-based compensation expense as of September 30, 2026, which will be recognized over a period of approximately years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||